The potential for NT-219 to be effective across several oncology therapies is what makes it a potential blockbuster drug. A great example is NT-219’s potential to convert non-responders to responders with Merck's (MRK) Keytruda (Figure 8)." $MRK $KTOV 
https://t.co/Xk83dFiBZQ